TargetMol

CPI-0610 carboxylic acid

Product Code:
 
TAR-T10879
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T10879-1mg1mg£493.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10879-5mg5mg£1,018.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10879-10mg10mg£1,340.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10879-25mg25mg£1,958.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10879-50mg50mg£2,625.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10879-100mg100mg£3,508.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
CPI-0610 carboxylic acid is a ligand for target protein for PROTAC. It is a potent bromodomain and extra-terminal (BET) protein inhibitor with the potential in the therapy of multiple myeloma.
CAS:
1380089-81-5
Formula:
C20H15ClN2O3
Molecular Weight:
366.8
Pathway:
Chromatin/Epigenetic
Purity:
0.98
SMILES:
Cc1noc2[C@H](CC(O)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12
Target:
Epigenetic Reader Domain

References

1. Albrecht BK, et al. Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials. J Med Chem. 2016 Feb 25;59(4):1330-9.